RNA-META, funded with DKK 60 million from the Novo Nordisk Foundation, will develop new types of RNA medicine and methods to deliver it to diseased cells for targeted disease treatment. It is led by Jørgen Kjems and includes 3 Co-PIs: Kurt Gothelf from Aarhus University, Louise Dalgaard from Roskilde University, and Markus Stoffel from ETH Zurich. Their common focus in the research centre will be to apply RNA therapeutics to metabolic diseases such as diabetes, fatty liver, renal fibrosis, and atherosclerosis.